Top

Autologous traNsplantation in elderly patients (≥70 years) with PCNSL: an EBMT Registry Analysis of Feasibility and Outcomes (ANNA Study)

Lymphoma Working Party (LWP)
Study type:
Retrospective Studies
Study number:
84032249
Type of treatment:
Autologous
Diseases:
Non-Hodgkin’s Lymphoma (NHL)
Short title:
Autologous transplantation in elderly PCNSL
Primary objective:
The main objective of this study is to evaluate the efficacy and safety of HDC-ASCT in patients
aged ≥70 years affected by PCNSL.
Key inclusion criteria:
1. Adult patients (age ≥70 years at the time of HDC-ASCT)
2. Diagnosis of primary DLBCL of the central nervous system (PCNSL) according to registry
categorization
3. Patients who received HDC-ASCT during their clinical history
Country:
All EBMT member countries
Principal investigator:
Dr. Teresa CALIMERI & Dr. Andrés J.M. Ferreri
EBMT Study coordinator:
Irma KHVEDELIDZE
Study coordinator email:
irma.khvedelidze@ebmt.org
EBMT Study Unit:
Paris Study Unit
Reason for processing personal data:
Patients’ data is needed to be able to identify the patient and calculate age at any time (impact on SAEs and response to clinical medications). Health care personal data is part of the CV collected for evidence of proper qualification for running the trial.
Categories of personal data collected:
DOB/YOB, gender
Medical data already reported to the EBMT Registry
Study Specific Questionnaire (MED-C)
Recipients who may access the data:
Paris Study Unit
Statistical Unit
3rd-party processors of Personal Data on behalf of EBMT/Service provider:
No

Privacy notices

Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)

Data Protection Impact Assessments

Rights available to individuals:
Access
Data portability
Rectification
Objection
Deletion
Is a Data Protection Impact Assessment required?:
DPIA performed for EBMT Registry (WP & NIS Studies)
Retention Schedule (if possible):
at least 5 years after the final report or first publication of study results